MYELOPEROXIDASE IN EXHALED BREATH CONDENSATE REFLECTS THE STATUS OF LUNG PARENCHYMA DURING THE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

NANCY TATEOSIAN, CATALINA KEHOE WILSON, PAULO C. MAFFIA, H. EDUARDO CHULUYAN, JUAN ANTONIO MAZZEI

Copenhague, Dinamarca

Congreso; 15th European Respiratory Society; 2005

European Respiratory Society

ABSTRACT Different markers of inflammation could be useful tool to monitor exacerbations ofchronic obstructive pulmonary disease (COPD). The aim of the present study were to determine the level of exhaled breath condensate (EBC) inflammatory mediators in exacerbate COPD patients and to find correlations with spirometry parameters. For this, 23 healthy subjects and 23 patients with exacerbate COPD were studied. The concentration of myeloperoxidase (MPO), IFNg and secretory leukocyte protease inhibitor (SLPI) in EBC was measured by immunoassays. The levels of MPO in COPD patients were significantly higher compared to healthy subjects (25 ± 5.5 vs 7 ± 3.3, p = 0.023). In contrast the concentration of IFNg and SLPI were lower in COPD patients compared to healthy volunteers. A negative correlation was found between IFNg and MPO, and IFNg and SLPI. We did not find any correlation among MPO and FEV1 or FEV1/vital capacity, and SLPI or IFNg with any of the spirometric parameters. Neither we observed correlation with GOLD stage of COPD. However, we found a very significant correlation of r = 0.7224 (p = 0.0053) with FVC values. We conclude that the levels of MPO in EBC from exacerbate COPD patients could be useful markers that reflect the immunology status and the response to treatment of lung parenchyma during the exacerbation of the illness.